CClinicalTrials.gg
Not yet recruitingNCT07846189REACT-PDUpdated Sep 29, 2026

Rhythmic Entrainment and Alertness in Lewy Body Dementia

An interventional study of Rhythmic Auditory Cueing in Dementia With Lewy Bodies (DLB) and Lewy Body Dementia (LBD), sponsored by Johns Hopkins University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study will examine how people with dementia with Lewy bodies (DLB) or mild cognitive impairment with Lewy bodies respond to rhythmic auditory cues, and whether changes in alertness affect ability to synchronize movements to a rhythm.

Participants will complete a single study visit that includes finger-tapping tasks performed with and without rhythmic auditory cues at different tempos. Brain activity will be recorded using electroencephalography (EEG), and tapping performance will be measured. Participants and the participant's study partners will also provide repeated ratings of alertness during the visit.

The study aims to identify brain and behavioral measures of rhythmic synchronization and determine whether these measures change depending on a participant's level of alertness. The findings will help guide the development of future rhythm-based interventions for people with DLB.

Read the detailed description

REACT-DLB is a single-session, within-participant mechanistic study designed to characterize neural and behavioral responses to rhythmic auditory cueing in individuals with probable dementia with Lewy bodies (DLB) or mild cognitive impairment with Lewy bodies. The target enrollment is 30 participants with a Clinical Dementia Rating (CDR) global score of 0.5-1.0, with balanced recruitment across CDR 0.5 and 1.0 when feasible.

Participants will first complete a self-paced finger-tapping trial to determine the participant's preferred tapping tempo. Participants will then complete six auditory-cued tapping trials at three tempo conditions: preferred tempo, 20% slower than preferred tempo, and 20% faster than preferred tempo. The tempo conditions will be presented in randomized order. EEG and finger-tapping responses will be recorded during the task.

The primary neural measure of rhythmic entrainment is beta-band event-related desynchronization (β-ERD), and the primary behavioral measure is inter-tap-interval coefficient of variation (ITI-CV). Exploratory measures include delta/theta inter-trial phase coherence (ITPC), mean asynchrony between taps and auditory cues, and continuation drift.

To evaluate whether momentary alertness influences rhythmic entrainment, participants and care partners will provide repeated Visual Analogue Scale ratings of alertness between tapping blocks, and brief eyes-open resting-state EEG recordings will be collected. The EEG theta/alpha ratio will be used as a neural index of alertness. Clinician- and care-partner-reported measures of cognitive fluctuation will also be collected. Analyses will examine whether alertness measures are associated with differences in neural and behavioral rhythmic entrainment.

For participants taking levodopa, study testing will be scheduled during the participant's best clinically defined ON state when applicable. If a clear best ON state cannot be identified, testing will occur within approximately one hour of medication administration. Participants not taking levodopa will be tested in the participant's usual clinically stable medication state.

The active finger-tapping component lasts approximately 13 minutes. Including rest periods and alertness assessments, the tapping-related portion is expected to take approximately 20-25 minutes. The entire study visit, including consent, questionnaires, EEG setup and recording, tapping tasks, and breaks, is expected to last approximately 90-120 minutes.

02

Conditions studied

  • Dementia With Lewy Bodies (DLB)
  • Lewy Body Dementia (LBD)

Browse trials for

Keywords

  • rhythmic auditory stimulation
  • rhythmic entrainment
  • auditory-motor synchronization
  • electroencephalography (EEG)
  • alertness
  • cognitive fluctuations
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of probable dementia with Lewy bodies (DLB) or mild cognitive impairment with Lewy bodies (MCI-LB) based on established clinical diagnostic criteria
  • Fluent in English
  • Able to attend with a study partner who can complete care-partner-reported cognitive fluctuation measures
  • Clinical Dementia Rating (CDR) global score of 0.5-1.0
  • Adequate upper-limb motor function, defined as Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III finger-tapping item (3.4) score ≤2 on at least one hand and ability to sustain rhythmic tapping for at least 10 seconds at approximately 1-3 Hz during a brief practice trial
  • Adequate hearing, corrected if necessary, to perceive rhythmic auditory cues
  • Stable on all medications for at least 30 days before enrollment

Exclusion criteria

Exclusion Criteria:

  • Age younger than 18 years
  • CDR global score ≥2.0
  • Severe upper-limb impairment, defined as MDS-UPDRS Part III finger-tapping item (3.4) score ≥3 in the dominant hand, or inability to produce more than 10 consecutive taps at ≥1 Hz despite instruction/practice
  • Other neurological, musculoskeletal, or sensory conditions that preclude safe or reliable task participation
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Auditory-Cued Finger Tapping

    Participants will complete a single-session finger-tapping protocol. After a 1-minute self-paced tapping trial to determine preferred tempo, participants will complete six 2-minute auditory-cued tapping trials at three tempo conditions: preferred tempo, 20% slower, and 20% faster, with each condition repeated twice in randomized order. EEG and tapping responses will be recorded during the task, and alertness will be assessed between tapping blocks.

    Behavioral: Rhythmic Auditory Cueing

Interventions

  • BehavioralRhythmic Auditory Cueing

    Participants will perform finger-tapping tasks while listening to rhythmic auditory cues presented at three tempo conditions: preferred tempo, 20% slower, and 20% faster. Each cued condition will be repeated twice in randomized order.

05

What researchers measure

Primary outcomes

  1. Beta-band event-related desynchronization (β-ERD) during auditory-cued finger tapping

    Beta-band event-related desynchronization (β-ERD; 13-30 Hz) will be derived from task-related EEG recorded during auditory-cued finger tapping. β-ERD is an EEG measure of sensorimotor activation and auditory-motor coupling during rhythmic movement. β-ERD will be compared across the three auditory cueing tempo conditions: preferred tempo, 20% slower than preferred tempo, and 20% faster than preferred tempo. Collected at a single study visit; during six 2-minute auditory-cued finger-tapping trials.

    Time frame: Day 1, during each of six 2-minute auditory-cued finger-tapping trials

  2. Inter-tap interval coefficient of variation (ITI-CV) during auditory-cued finger tapping

    Inter-tap interval coefficient of variation (ITI-CV) will be calculated from the timing of consecutive finger taps during auditory-cued finger tapping. ITI-CV measures variability in tapping intervals and serves as an index of motor-timing precision and rhythmic consistency, with lower values indicating more consistent tapping. ITI-CV will be compared across the three auditory cueing tempo conditions: preferred tempo, 20% slower than preferred tempo, and 20% faster than preferred tempo. Collected at a single study visit; during six 2-minute auditory-cued finger-tapping trials.

    Time frame: Day 1, during each of six 2-minute auditory-cued finger-tapping trials

Secondary outcomes

  1. EEG Alertness Index as assessed by theta/alpha ratio (TAR)

    The EEG Alertness Index will be calculated as the frontal theta/posterior alpha ratio (TAR) from eyes-open resting-state EEG recordings collected between finger-tapping blocks. TAR is an EEG marker of cortical arousal, with higher TAR indicating lower alertness. TAR will be examined in relation to neural and behavioral rhythmic entrainment across auditory cueing conditions. Collected at a single study visit; during 2-minute eyes-open resting-state EEG recordings collected between tapping blocks

    Time frame: Day 1, during each 2-minute eyes-open resting-state EEG recording collected between finger-tapping blocks

  2. Participant-reported alertness as assessed by Visual Analogue Scale (VAS)

    Participants will provide repeated Visual Analogue Scale ratings of their momentary alertness between finger-tapping blocks. These ratings will be used to characterize within-session variation in alertness and examine its relationship with neural and behavioral measures of rhythmic entrainment. Scale 1-10 lower score better. Collected at a single study visit; assessed between tapping blocks.

    Time frame: Day 1, immediately after each of six 2-minute auditory-cued finger-tapping trials

  3. Care-partner-reported participant alertness as assessed by Visual Analogue Scale (VAS)

    Care partners will provide repeated Visual Analogue Scale ratings of the participant's momentary alertness between finger-tapping blocks. These ratings will provide an additional measure of within-session alertness variation and will be examined in relation to neural and behavioral measures of rhythmic entrainment. Scale 1-10 lower score better. Collected at a single study visit; assessed between tapping blocks.

    Time frame: Day 1, immediately after each of six 2-minute auditory-cued finger-tapping trials

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Baik K, Jung JH, Jeong SH, Chung SJ, Yoo HS, Lee PH, Sohn YH, Kang SW, Ye BS. Implication of EEG theta/alpha and theta/beta ratio in Alzheimer's and Lewy body disease. Sci Rep. 2022 Nov 4;12(1):18706. doi: 10.1038/s41598-022-21951-5. PubMed 36333386 ↗
  • Pantelyat A, Dayanim G, Kang K, Turk B, Pagkatipunan R, Huenergard SK, Mears A, Bang J. Rhythmic auditory cueing in atypical parkinsonism: A pilot study. Front Neurol. 2022 Oct 28;13:1018206. doi: 10.3389/fneur.2022.1018206. eCollection 2022. PubMed 36388209 ↗
  • Stylianou M, Murphy N, Peraza LR, Graziadio S, Cromarty R, Killen A, O' Brien JT, Thomas AJ, LeBeau FEN, Taylor JP. Quantitative electroencephalography as a marker of cognitive fluctuations in dementia with Lewy bodies and an aid to differential diagnosis. Clin Neurophysiol. 2018 Jun;129(6):1209-1220. doi: 10.1016/j.clinph.2018.03.013. Epub 2018 Apr 3. PubMed 29656189 ↗
  • Donaghy PC, Carrarini C, Ferreira D, Habich A, Aarsland D, Babiloni C, Bayram E, Kane JP, Lewis SJ, Pilotto A, Thomas AJ, Bonanni L; Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Lewy Body Dementias Prodromal Working Group. Research diagnostic criteria for mild cognitive impairment with Lewy bodies: A systematic review and meta-analysis. Alzheimers Dement. 2023 Jul;19(7):3186-3202. doi: 10.1002/alz.13105. Epub 2023 Apr 24. PubMed 37096339 ↗
  • McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100. doi: 10.1212/WNL.0000000000004058. Epub 2017 Jun 7. PubMed 28592453 ↗
  • D'Antonio F, Kane JPM, Ibanez A, Lewis SJG, Camicioli R, Wang H, Yu Y, Zhang J, Ji Y, Borda MG, Kandadai RM, Babiloni C, Bonanni L, Ikeda M, Boeve BF, Leverenz JB, Aarsland D; ISTAART Lewy body dementias Consortia Working Group. Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. Alzheimers Dement (Amst). 2021 Sep 14;13(1):e12235. doi: 10.1002/dad2.12235. eCollection 2021. PubMed 34541289 ↗
  • Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther. 2014 Nov 21;6(9):82. doi: 10.1186/s13195-014-0082-1. eCollection 2014. PubMed 25419243 ↗
  • Mueller C, Ballard C, Corbett A, Aarsland D. The prognosis of dementia with Lewy bodies. Lancet Neurol. 2017 May;16(5):390-398. doi: 10.1016/S1474-4422(17)30074-1. Epub 2017 Mar 22. PubMed 28342649 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT07846189
Lead sponsor
Johns Hopkins University
Collaborators
National Institute on Aging (NIA)
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Kyurim Kang, PhD
Contact
kkang19@jhmi.edu
410-614-5671
Alexander Pantelyat, MD
Contact
apantel1@jhmi.edu
4105023290
Kyurim Kang, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion